Perception vs Reality; Building a Decision Team; Active Surveillance Prevails

A pivotal clinical trial of the antibody-drug conjugate mirvetuximab soravtansine met the primary endpoint of objective response in previously treated ovarian cancer, ImmunoGen announced.

An oncologist learns an important lesson about disconnect between perception and reality. (JCO Art of Oncology)

An older breast cancer patient nearing end of life, who also happens to be a physician, makes difficult treatment decisions with input from a “health team” of family and close friends she brought together almost 8 years ago. (Kaiser Health News)

The FDA approved pafolacianine (Cytalux), an imaging agent that helps surgeons identify ovarian cancers more clearly.

Use of statins to lower cholesterol may affect results of screening for prostate cancer. (Tampere University, JAMA Oncology)

Say what? Olema Oncology issued a statement denouncing the release of “falsified” information on Twitter about an upcoming presentation on its investigational breast cancer drug OP-1250, followed a day later by another statement that included most of the same information.

Following discussions with the FDA, Secura Bio has voluntarily withdrawn accelerated approval of the company’s histone deacetylase inhibitor panobinostat (Farydak) for use in combination therapy for previously treated multiple myeloma.

In a complete response letter to BeyondSpring Pharmaceuticals, the FDA said the evidence submitted to date does not support approval of the selective immunomodulating microtubule binding agent plinabulin, in combination with G-CSF, to prevent chemotherapy-induced neutropenia.

Janssen Pharmaceuticals announced FDA expansion of indications for daratumumab and hyaluronidase-fihj (Darzalex Faspro) to include combination therapy with carfilzomib (Kyprolis) and dexamethasone for certain patients with previously treated multiple myeloma.

Responding to pushback from urologists and patient advocates, the National Comprehensive Cancer Network reversed course and reinstated active surveillance as the preferred initial treatment strategy for “most” men with newly diagnosed localized prostate cancer.

The San Antonio Breast Cancer Symposium begins Tuesday and continues through December 10, and MedPage Today will have complete coverage.